- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Beleave Sponsors Don't Drive Hi Campaign Aimed to Reduce Cannabis Impaired Driving
Beleave Inc. (CSE: BE) (CSE: BE.CN) (CNSX: BE) (“Beleave” or the “Company”) is pleased to be a sponsor and supporter of the Don’t Drive Hicampaign, a campaign aimed to reduce cannabis impaired driving. With legislation for legalizing marijuana progressing, the year-long Don’t Drive Hicampaign is backed by prominent sponsors including advertising agency BBDO, radio stations Z103.5 and Energy …
“Keeping our roads safe from tragedy is the focus of our Don’t Drive Hicampaign and we are particularly grateful to Beleave for lending their support to this important initiative,” said Lorne Simon, a leading safe driving advocate and founder of R.I.D.E. CHECKS. “Being backed by Beleave, a respected and forward-thinking company, is paramount to the success of the campaign and creating a culture where driving after consuming cannabis is never okay. Together we can spread awareness about being responsible and the devastating impact and consequences of driving drugged.”
Read more about the Don’t Drive Hi campaign here.
“It’s wonderful to see great communication, public education, and prevention initiatives like the Don’t Drive Hi campaign, that are committed to protecting Canadians by reducing the risks associated with cannabis impairment and driving,” commented Beleave CEO Dr. Roger Ferreira. “Beleave is proud to support the Don’t Drive Hi campaign in an effort to minimize the social costs and harms attributed to cannabis-related motor vehicle collisions in Canada.”
About Beleave
Beleave Inc. is a biotech company and Beleave’s wholly-owned subsidiary First Access Medical Inc. (“FAM”) is a licensed producer pursuant to the ACMPR. Beleave’s purpose-built facility is in Hamilton, Ontario.
Forward-Looking Statements
This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the completion of the ACMPR licensing process, meeting the requirements of the ACMPR, obtaining a license to cultivate pursuant to the ACMPR, and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.
For more information contact:
Sebastian de Kloet
Phone: 1 (905) 979 – 5173
Email: Sebastian@beleave.com
www.beleave.com
Click here to connect with Beleave Inc. (CNSX:BE) to receive an Investor Presentation
Source: www.benzinga.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.